[go: up one dir, main page]

WO2021116503A8 - Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds - Google Patents

Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds Download PDF

Info

Publication number
WO2021116503A8
WO2021116503A8 PCT/EP2021/060750 EP2021060750W WO2021116503A8 WO 2021116503 A8 WO2021116503 A8 WO 2021116503A8 EP 2021060750 W EP2021060750 W EP 2021060750W WO 2021116503 A8 WO2021116503 A8 WO 2021116503A8
Authority
WO
WIPO (PCT)
Prior art keywords
deuterated
dimethyltryptamine
compounds
compound
therapeutic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/060750
Other languages
French (fr)
Other versions
WO2021116503A2 (en
WO2021116503A3 (en
Inventor
Peter RANDS
Tiffanie BENWAY
Zelah JOEL
Marie LAYZELL
Ellen James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Small Pharma Ltd
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Priority claimed from US17/108,679 external-priority patent/US20220168274A1/en
Priority claimed from GBGB2018950.2A external-priority patent/GB202018950D0/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Priority to KR1020227045704A priority Critical patent/KR102589605B1/en
Priority to AU2021204158A priority patent/AU2021204158B2/en
Priority to EP21720509.5A priority patent/EP3902541B1/en
Priority to ES21720509T priority patent/ES2928395T3/en
Priority to NZ794833A priority patent/NZ794833A/en
Priority to MX2022014900A priority patent/MX2022014900A/en
Priority to PL21720509.5T priority patent/PL3902541T3/en
Priority to IL298541A priority patent/IL298541B2/en
Priority to JP2022574099A priority patent/JP7288154B2/en
Priority to CA3179161A priority patent/CA3179161C/en
Priority to CN202180046463.XA priority patent/CN116056763B/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Priority to AU2021284861A priority patent/AU2021284861A1/en
Priority to GB2106881.2A priority patent/GB2595776B/en
Priority to US17/320,155 priority patent/US12042564B2/en
Priority to CN202180046533.1A priority patent/CN115996713A/en
Priority to CA3118556A priority patent/CA3118556A1/en
Priority to PCT/EP2021/062794 priority patent/WO2021244831A1/en
Priority to EP21725377.2A priority patent/EP4149460B8/en
Priority to IL298542A priority patent/IL298542B2/en
Priority to JP2022574098A priority patent/JP7579888B2/en
Priority to EP24215587.7A priority patent/EP4494703A3/en
Publication of WO2021116503A2 publication Critical patent/WO2021116503A2/en
Publication of WO2021116503A8 publication Critical patent/WO2021116503A8/en
Priority to US17/458,167 priority patent/US11471417B2/en
Priority to PCT/EP2021/082227 priority patent/WO2022117359A1/en
Priority to IL303288A priority patent/IL303288A/en
Priority to JP2023533243A priority patent/JP2023551058A/en
Priority to TW110143066A priority patent/TWI891942B/en
Priority to AU2021391581A priority patent/AU2021391581A1/en
Priority to EP21815486.2A priority patent/EP4031529B1/en
Priority to CA3203020A priority patent/CA3203020A1/en
Priority to EP23198784.3A priority patent/EP4275753A3/en
Priority to CN202180090269.1A priority patent/CN116761599B/en
Priority to EP21816489.5A priority patent/EP4255421A1/en
Priority to PCT/EP2021/083755 priority patent/WO2022117640A1/en
Priority to US18/252,949 priority patent/US20240016782A1/en
Priority to US17/680,411 priority patent/US11660289B2/en
Anticipated expiration legal-status Critical
Priority to US18/163,388 priority patent/US12251371B2/en
Publication of WO2021116503A3 publication Critical patent/WO2021116503A3/en
Priority to US18/748,483 priority patent/US20240342101A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a deuterated N,N-dimethyltryptamine compound or a plurality of deuterated N,N-dimethyltryptamine compounds for use in therapy, selected from N,N-dimethyltryptamine compounds, α-protio, α-deutero-N,N- dimethyltryptamine compounds, α,α-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds, preferably wherein the deuterated N,N-dimethyltryptamine compound has an increased half-life when compared with the half-life of undeuterated N,N-dimethyltryptamine. In particular the invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof; (I) wherein the ratio of deuterium:protium in the compound is greater than that found naturally in hydrogen; each R1 is independently selected from H and D; R2 is selected from CH3 and CD3; R3 is selected from CH3 and CD3; and each yH is independently selected from H and D. Methods of synthesising compounds of the present invention, and methods of use of such compositions in treating psychiatric or neurological disorders, such as major depressive disorder, are also provided.
PCT/EP2021/060750 2020-06-02 2021-04-23 Deuterated compounds Ceased WO2021116503A2 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
CN202180046463.XA CN116056763B (en) 2020-06-02 2021-04-23 Therapeutic compositions containing deuterated or partially deuterated N,N-dimethyltryptamine compounds
CA3179161A CA3179161C (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
JP2022574099A JP7288154B2 (en) 2020-06-02 2021-04-23 Therapeutic compositions containing deuterated or partially deuterated N,N-dimethyltryptamine compounds
AU2021204158A AU2021204158B2 (en) 2020-06-02 2021-04-23 Deuterated compounds
KR1020227045704A KR102589605B1 (en) 2020-06-02 2021-04-23 Therapeutic composition comprising a deuterated or partially deuterated N,N-dimethyltryptamine compound
EP21720509.5A EP3902541B1 (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
ES21720509T ES2928395T3 (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compounds
NZ794833A NZ794833A (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
MX2022014900A MX2022014900A (en) 2020-06-02 2021-04-23 Deuterated compounds.
PL21720509.5T PL3902541T3 (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
IL298541A IL298541B2 (en) 2020-06-02 2021-04-23 1,1-dideuterio-2-(1h-indol-3-yl)-n,n-bis(trideuteriomethyl)ethanamine and therapeutic composition comprising it
IL298542A IL298542B2 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms comprising deuterated n,n-dimethyltryptamine compounds and salts thereof
JP2022574098A JP7579888B2 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
EP24215587.7A EP4494703A3 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
GB2106881.2A GB2595776B (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
PCT/EP2021/062794 WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
EP21725377.2A EP4149460B8 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/320,155 US12042564B2 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
CN202180046533.1A CN115996713A (en) 2020-06-02 2021-05-13 Therapeutic Solid Dosage Forms
CA3118556A CA3118556A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
AU2021284861A AU2021284861A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/458,167 US11471417B2 (en) 2020-06-02 2021-08-26 Deuterated N,N-dimethyltryptamine compounds
CA3203020A CA3203020A1 (en) 2020-12-01 2021-11-18 Deuterated compounds
IL303288A IL303288A (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP23198784.3A EP4275753A3 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds
PCT/EP2021/082227 WO2022117359A1 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP21815486.2A EP4031529B1 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds
CN202180090269.1A CN116761599B (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated N, N-dimethyltryptamine compounds
JP2023533243A JP2023551058A (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated N,N-dimethyltryptamine compounds
TW110143066A TWI891942B (en) 2020-12-01 2021-11-18 Deuterated compounds
AU2021391581A AU2021391581A1 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP21816489.5A EP4255421A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
US18/252,949 US20240016782A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
PCT/EP2021/083755 WO2022117640A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
US17/680,411 US11660289B2 (en) 2020-12-01 2022-02-25 Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US18/163,388 US12251371B2 (en) 2020-12-01 2023-02-02 Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US18/748,483 US20240342101A1 (en) 2020-06-02 2024-06-20 Therapeutic solid dosage forms

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US16/890,664 2020-06-02
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
US16/890,664 US11771681B2 (en) 2019-06-03 2020-06-02 Therapeutic compounds
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
EPPCT/EP2020/065244 2020-06-02
GB2008303.6 2020-06-02
GB2018950.2 2020-12-01
US17/108,679 US20220168274A1 (en) 2020-12-01 2020-12-01 Parenteral Formulation
GB2018955.1 2020-12-01
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,938 2020-12-01
US17/108,679 2020-12-01
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 2021-03-22
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
GB2103981.3 2021-03-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/458,167 Continuation US11471417B2 (en) 2020-06-02 2021-08-26 Deuterated N,N-dimethyltryptamine compounds

Publications (3)

Publication Number Publication Date
WO2021116503A2 WO2021116503A2 (en) 2021-06-17
WO2021116503A8 true WO2021116503A8 (en) 2021-08-12
WO2021116503A3 WO2021116503A3 (en) 2023-09-28

Family

ID=76329655

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2021/060750 Ceased WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds
PCT/EP2021/062794 Ceased WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/062794 Ceased WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms

Country Status (8)

Country Link
EP (3) EP3902541B1 (en)
JP (1) JP7579888B2 (en)
CN (1) CN115996713A (en)
AU (1) AU2021284861A1 (en)
CA (1) CA3118556A1 (en)
GB (1) GB2595776B (en)
IL (1) IL298542B2 (en)
WO (2) WO2021116503A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122741B2 (en) 2020-08-18 2024-10-22 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3873883B1 (en) 2019-11-07 2022-12-21 Small Pharma Ltd Method of synthesis
MX2022009528A (en) 2020-02-04 2022-11-14 Mindset Pharma Inc 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONINERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS.
KR20220137081A (en) 2020-02-04 2022-10-11 마인드셋 파마 인크. Silosin derivatives as serotonergic psychedelic agonists for the treatment of CNS disorders
CA3182156A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
AU2021318431C1 (en) * 2020-07-29 2023-11-30 Monster Color Carnival Llc Delivery system for ayahuasca-like substances
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4255421A1 (en) 2020-12-01 2023-10-11 Small Pharma Ltd Inhalable formulations
IL303288A (en) * 2020-12-01 2023-07-01 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2022120181A1 (en) 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
WO2022261383A1 (en) 2021-06-09 2022-12-15 ATAI Life Sciences AG Novel prodrugs and conjugates of dimethyltryptamine
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
MX2024005955A (en) 2021-11-18 2024-06-11 Cybin Uk Ltd Injectable and inhalable formulations.
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
AU2023207801A1 (en) * 2022-01-14 2024-06-27 Cybin Irl Limited Tryptamine compositions and methods
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2023186963A1 (en) * 2022-03-31 2023-10-05 Cybin Irl Limited Combination of nitrous oxide and 5-ht2a receptor agonists
EP4522167A1 (en) 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010356A1 (en) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-HALOGEN TRIPTAMIN DERIVATIVES USEFUL AS LIGANDS OF THE 5-HT6 AND / OR 5-HT7 SEROTONIN RECEPTOR.
JP6367545B2 (en) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド Deuterated derivatives of ruxolitinib
MA50786A (en) * 2017-10-26 2022-04-27 Blumentech S L COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3873883B1 (en) * 2019-11-07 2022-12-21 Small Pharma Ltd Method of synthesis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122741B2 (en) 2020-08-18 2024-10-22 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use

Also Published As

Publication number Publication date
WO2021116503A2 (en) 2021-06-17
GB2595776B (en) 2023-05-24
IL298542A (en) 2023-01-01
GB202106881D0 (en) 2021-06-30
CA3118556A1 (en) 2021-12-02
EP4149460A1 (en) 2023-03-22
GB2595776A (en) 2021-12-08
IL298542B1 (en) 2024-10-01
EP4494703A2 (en) 2025-01-22
AU2021284861A1 (en) 2023-01-05
WO2021116503A3 (en) 2023-09-28
JP2023527575A (en) 2023-06-29
EP3902541A2 (en) 2021-11-03
EP4149460C0 (en) 2024-11-27
EP4494703A3 (en) 2025-04-02
JP7579888B2 (en) 2024-11-08
EP4149460B1 (en) 2024-11-27
IL298542B2 (en) 2025-02-01
EP4149460B8 (en) 2025-01-08
EP3902541B1 (en) 2022-09-14
CN115996713A (en) 2023-04-21
WO2021244831A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
WO2021116503A8 (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
PH12022551661A1 (en) Mek inhibitors and therapeutic uses thereof
EP4275753A3 (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
EA202193338A1 (en) THERAPEUTIC COMPOSITIONS INCLUDING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS
MX2025000642A (en) Macrocycle compounds for the treatment of cancer
MX2022013647A (en) Imidazopyridazines as modulators of il-17.
MY127181A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MXPA05006420A (en) Pyrimidine derivates for the treatment of abnormal cell growth.
MX2023006883A (en) Methods of treating prostate cancer.
GB0226724D0 (en) Therapeutic agents
MX2019006296A (en) Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases.
YU30702A (en) Novel benzimidazole derivatives useful as antiproliferate agents
MX2022014192A (en) Methods of treating prostate cancer.
BG104372A (en) (benzodioxan, benzofuran or benzopyran) derivatives possessing fundus relaxing properties
MX2024008462A (en) MEK IMMUNOGYNECOLOGY INHIBITORS AND THEIR THERAPEUTIC USES.
CR20250329A (en) Tricyclic compounds for the treatment of cancer
PH12012500867A1 (en) Ethynyl derivatives
WO2012122028A3 (en) Pyrazinoisoquinoline compounds
MX2022014900A (en) Deuterated compounds.
FI2968346T3 (en) Methods and compositions for gamma-glutamyl cycle modulation
ZA202400821B (en) Inhibitors of transglutaminases
PH12021552110A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
MX2023009285A (en) Novel compounds.
MX2024002674A (en) Thiadiazolone derivatives useful as ampk activator.
CA2511242A1 (en) Inhibitors of human tumor-expressed ccxckr2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21720509

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021720509

Country of ref document: EP

Effective date: 20210729

ENP Entry into the national phase

Ref document number: 3179161

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022574099

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022024566

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227045704

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202217076779

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021204158

Country of ref document: AU

Date of ref document: 20210423

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022024566

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221130